These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2696563)

  • 1. Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?
    Roux-Dosseto M; Romain S; Dussault N; Martin PM
    Biomed Pharmacother; 1989; 43(9):641-9. PubMed ID: 2696563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification.
    Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F
    Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis.
    Børresen AL; Ottestad L; Gaustad A; Andersen TI; Heikkilä R; Jahnsen T; Tveit KM; Nesland JM
    Br J Cancer; 1990 Oct; 62(4):585-90. PubMed ID: 1977466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
    Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
    Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.
    Keshgegian AA
    Breast Cancer Res Treat; 1995 Aug; 35(2):201-10. PubMed ID: 7647342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
    Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oncogene organization and expression in breast cancer exemplified by proto-oncogene c-erb B2].
    Friedrichs K; Jonat W; Meybohm J; Singh S
    Arch Gynecol Obstet; 1989; 245(1-4):658-60. PubMed ID: 2572202
    [No Abstract]   [Full Text] [Related]  

  • 12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
    Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
    Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2 amplification in tubular carcinoma of the breast.
    Oakley GJ; Tubbs RR; Crowe J; Sebek B; Budd GT; Patrick RJ; Procop GW
    Am J Clin Pathol; 2006 Jul; 126(1):55-8. PubMed ID: 16753605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
    Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
    Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.
    Lampe B; Genz T; Maassen V; Mikorey S; Klosterhalfen T
    Arch Gynecol Obstet; 1992; 251(1):45-50. PubMed ID: 1347986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer.
    Barrow TM; Barault L; Ellsworth RE; Harris HR; Binder AM; Valente AL; Shriver CD; Michels KB
    Int J Cancer; 2015 Aug; 137(3):537-47. PubMed ID: 25560175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
    Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
    World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.